A collaboration between HiRO and Differentia combines HiRO’s global clinical operations, data science, and real-world data expertise with Differentia’s AI-driven digital twin and modeling platforms to enable simulation-informed trial design and decision-making.

HiRO is a global CRO with more than 30 years of experience, 500+ professionals, and 1,600 trials in 85 countries, spanning oncology, rare diseases, and advanced modalities.

Background notes HiRO’s trial experience and Differentia’s AI-powered digital twin technology for drug development.

Lasfit designs F-150 products around the vehicle’s exact configuration, emphasizing vehicle-centric development to ensure proper fit, heat management, and installation feasibility.

Objectives include developing new products and commercial solutions built on combined simulation capabilities and enabling smarter patient selection, potential trial size reductions, and faster development timelines.

The collaboration is expected to yield high-fidelity digital twins and integrated simulation capabilities that de-risk assets in virtual environments and improve sponsor ROI.

The partnership targets improved trial design, smarter patient selection, potential reduction in the number of subjects, and earlier sponsor decision-making across complex indications such as oncology, rare diseases, cell and gene therapies, and radiopharmaceuticals.

The aim is to enable simulation-informed decision-making, improve trial design, manage risk, and accelerate timelines across oncology, rare diseases, cell and gene therapies, radiopharmaceuticals, and other complex indications.

Kas Subramanian of Differentia emphasizes creating high-fidelity digital twins to de-risk assets and run more efficient trials, signaling a paradigm shift in drug development.

Kas Subramanian, CEO and Co-Founder of Differentia, notes that AI-powered digital twins combining biosimulations will streamline trials and de-risk assets.

HiRO and Differentia plan to disclose more details on specific collaborative initiatives as the partnership progresses.

The agreement is formalized as a Memorandum of Understanding to jointly develop clinical trial simulation capabilities and create new product offerings built on those capabilities.